

Resource Summary Report

Generated by [NIF](#) on Sep 10, 2026

SW1990

RRID:CVCL_1723

Type: Cell Line

Proper Citation

RRID:CVCL_1723

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1723

Proper Citation: RRID:CVCL_1723

Description: Cell line SW1990 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Pancreatic adenocarcinoma

Defining Citation: [PMID:6871872](#), [PMID:12068308](#), [PMID:15126341](#), [PMID:15688027](#), [PMID:17217822](#), [PMID:18380791](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:21054984](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:25167228](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26216984](#), [PMID:26589293](#), [PMID:27067801](#), [PMID:27259358](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29444439](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31452783](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., From: Scott and White Clinic; Temple; USA., Part of: NCI RAS program mutant KRAS cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SW1990

Synonyms: SW-1990, SW 1990

Cross References: BTO:BTO_0003491, CLO:CLO_0009192, CLO:CLO_0009194, EFO:EFO_0002365, CLDB:cl4438, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-

3610, ATCC:CRL-2172, BioGRID_ORCS_Cell_line:1029, BioSample:SAMN03472179, BioSample:SAMN10987630, cancercellines:CVCL_1723, CCRID:1101HUM-PUMC000472, CCRID:3101HUMTCHu201, CCRID:4201HUM-CCTCC00246, CCTCC:GDC0246, Cell_Model_Passport:SIDM01165, CGH-DB:184-1, CGH-DB:9275-4, ChEMBL-Cells:ChEMBL3308789, ChEMBL-Targets:ChEMBL1075592, CLS:305068, Cosmic:724871, Cosmic:910907, Cosmic:913312, Cosmic:1609543, Cosmic:2434093, Cosmic-CLP:910907, DepMap:ACH-000155, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:910907, GEO:GSE79953, GEO:GSM206550, GEO:GSM621893, GEO:GSM784708, GEO:GSM887672, GEO:GSM888764, GEO:GSM1024415, GEO:GSM1670506, IARC_TP53:27582, IGRhCellID:SW1990, KCB:KCB_2012113YJ, LiGeA:CCLE_709, LINCS_LDP:LCL-1750, MetaboLights:MTBLS9288, Pharmacodb:SW1990_1536_2019, PRIDE:PXD003198, PRIDE:PXD030304, Progenetix:CVCL_1723, PubChem_Cell_line:CVCL_1723, TOKU-E:3217, Ubigen:YC-C124, Wikidata:Q54971096

ID: CVCL_1723

Record Creation Time: 20220427T221615+0000

Record Last Update: 20260905T182522+0000

Ratings and Alerts

No rating or validation information has been found for SW1990.

No alerts have been found for SW1990.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 420 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Baars B, et al. (2026) RAS Mutation-Specific Responses to Paralog- and State-Selective RAS Inhibitors. Molecular cancer research : MCR, 24(1), 60.

Szigeti KA, et al. (2026) Antimetastatic effects of MRTX1133 KRAS G12D specific inhibitor in a liver metastatic model of pancreatic ductal adenocarcinoma. Scientific reports, 16(1), 4144.

Assi M, et al. (2026) Extracellular matrix sensing regulates intratumoral heterogeneity of autophagic flux. Cell, 189(6), 1731.

Zhang S, et al. (2026) Cancer cell-derived sialylated IgG interacting with Siglec-7/9/10 is a potential immunotherapeutic target in pancreatic cancer. Cell reports. Medicine, 7(3), 102660.

Woo SM, et al. (2026) Inhibiting Fatty Acid Oxidation Reverses Autophagy-Mediated Acquired Chemotherapy Resistance in Pancreatic Ductal Adenocarcinoma. *Cancer research*, 86(13), 3194.

Lin Q, et al. (2026) Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(11), 2279.

Wang F, et al. (2026) Lactate Facilitates the Survival and Invasion of Pancreatic Cancer Cells Under Glucose Deprivation. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 40(7), e71726.

Bevilacqua R, et al. (2026) Therapeutic vulnerabilities exposed by the 9p21 loss identified through multiparametric drug screening inform rational combination strategies. *NPJ precision oncology*, 10(1).

Deng X, et al. (2026) RBM15-Mediated m6A Modification Regulates Proliferation and Migration of Pancreatic Cancer Cells via the lncRNA LINC01320/miR-1287-5p/FBXO11 Axis. *Biomolecules & therapeutics*, 34(3), 618.

Xie L, et al. (2026) Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRASG12D Inhibitor. *Cancer discovery*, 16(5), 895.

Yang J, et al. (2026) A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(12), 2479.

Burge RA, et al. (2026) KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment. *Cancer research*, 86(8), 1868.

Zhu L, et al. (2026) The Effect of AZD5153 on Radiosensitivity in Pancreatic Cancer Cells Through ATM-chk1 Pathway. *Drug design, development and therapy*, 20, 568551.

Krishna Kumar N, et al. (2026) SLC22A3/OCT3 drives serotonin-mediated stemness in pancreatic cancer. *Cell reports*, 45(6), 117387.

Tang R, et al. (2026) Mapping cell type-resolved transcriptomic profiles to patient survival in pancreatic cancer. *Cancer cell*.

Qin G, et al. (2026) HDAC5 depletion promotes hyper-acetylation of FOXA1 and potentiates HIF1?? transcriptional activation in pancreatic cancer. *Molecular cell*, 86(14), 2794.

Bai Y, et al. (2026) USP20-RAB8A signaling axis restricts pancreatic cancer progression by disrupting GLUT1 vesicular trafficking and inhibiting glucose uptake. *Cancer letters*, 642, 218299.

Miyan J, et al. (2026) The combination of BCL-xL PROTAC and mTOR inhibitor sensitizes pancreatic ductal adenocarcinoma to KRAS G12D inhibitor treatment by enhancing

apoptosis induction. bioRxiv : the preprint server for biology.

Ning W, et al. (2026) A bispecific nanobody-drug conjugate targeting TROP2 and c-Met for low-concentration, single-dose treatment of pancreatic cancer. *Cell reports. Medicine*, 7(4), 102688.

Zhang Y, et al. (2026) Integrative multi-omics analysis identifies ATAD1 as a potential regulator of metastasis in pancreatic cancer. *Scientific reports*, 16(1).